Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-17, Stock:NVS, The news for the past five days is as follows:
2018-10-10: NEWS1: Novartis Presents Positive Data on Sickle Cell Disease Drug.NEWS2: Novartis Presents Positive Data on Sickle Cell Disease Drug.NEWS3: Novartis Announces Results From Phase IIIb ASSESS Study.NEWS4: Novartis Announces Results From Phase IIIb ASSESS Study.NEWS5: Could Johnson & Johnson Meet Its Q3 2018 Sales Estimates?.NEWS6: Novartis Presents Positive Data on Sickle Cell Disease Drug.NEWS7: Analysts’ Ratings for Johnson & Johnson before Its Q3 Earnings.NEWS8: Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus.NEWS9: Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus.NEWS10: Celgene: Multiple Myeloma Franchise Could Drive Growth.NEWS11: How Novartis’s Sandoz Business Has Been Performing Recently.NEWS12: A Closer Look at Novartis’s Innovative Medicines Segment.NEWS13: The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares.NEWS14: How Novartis’s Businesses Have Been Performing.NEWS15: Novartis To Present 33 Scientific Abstracts.NEWS16: Novartis To Present 33 Scientific Abstracts.
2018-10-11: NEWS1: Abbvie settles Humira patent disputes with Novartis unit.NEWS2: Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes.NEWS3: Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes.NEWS4: AbbVie stock ticks higher as Humira patent dispute with Novartis resolved.NEWS5: Wall Street Analysts See Upside Potential of 3.9% in TEVA.NEWS6: Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales.NEWS7: Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales.NEWS8: Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing.NEWS9: Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing.NEWS10: Novartis Presents Data on Multiple Sclerosis Drug Gilenya.NEWS11: Novartis Presents Data on Multiple Sclerosis Drug Gilenya.NEWS12: Novartis Presents Data on Multiple Sclerosis Drug Gilenya.NEWS13: Analysts’ Estimates and Ratings for Novartis in October.NEWS14: A Look at the Performance of Novartis’s Alcon.
2018-10-12: NEWS1: AbbVie Permits US Sale of Sandoz's Humira Biosimilar.NEWS2: 3 Large-Cap Pharma Stocks Performing Better Than Industry.NEWS3: 3 Large-Cap Pharma Stocks Performing Better Than Industry.NEWS4: Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal.NEWS5: Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal.NEWS6: AbbVie Settles With Novartis to Delay Humira Biosimilar in US.NEWS7: AbbVie Settles With Novartis to Delay Humira Biosimilar in US.NEWS8: Pharma Stock Roundup: ABBV, NVS&apos; Humira Biosimilar Agreement, BMY&apos;s New Cancer Deal.NEWS9: AbbVie Settles With Novartis to Delay Humira Biosimilar in US.NEWS10: Abbvie settles Humira patent disputes with Novartis unit.NEWS11: Abbvie settles Humira patent disputes with Novartis unit.
2018-10-15: NEWS1: Trump administration: Drug makers should disclose prices in TV ads.NEWS2: Novartis’ Estimates and Recommendations on October 12.NEWS3: Novartis in Q3 2018: Analysts Expect Revenue Growth.NEWS4: Novartis: What to Expect from Q3 Earnings on October 18.NEWS5: An Update on Bausch + Lomb/International in October.
2018-10-16: NEWS1: Alnylam to Pursue Full Approval & Rolling NDA for Givosiran.NEWS2: Alnylam to Pursue Full Approval & Rolling NDA for Givosiran.NEWS3: Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG.NEWS4: Benchmark Out Bullish On 'Well-Positioned' Tilray Ahead of Canada's Cannabis Legalization.NEWS5: Tilray Jumps After $200 Price Target and 'Buy' Rating: LIVE MARKETS BLOG.NEWS6: Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark.NEWS7: Roche Announces Positive Data on Breast Cancer Drug Kadcyla.NEWS8: Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU.NEWS9: Tilray&apos;s stock surges after Benchmark starts coverage with bullish rating, $200 target.NEWS10: Novartis To Present Five-year Data From Phase III Studies For Cosentyx.NEWS11: Novartis To Present Five-year Data From Phase III Studies For Cosentyx.

Answer: Decrease